KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Edwards Lifesciences (EW) Accumulated Depreciation & Amortization (2016 - 2025)

Edwards Lifesciences (EW) has 14 years of Accumulated Depreciation & Amortization data on record, last reported at $156.6 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 0.9% year-over-year to $156.6 million; the TTM value through Dec 2025 reached $156.6 million, up 0.9%, while the annual FY2025 figure was $156.6 million, 0.9% up from the prior year.
  • Accumulated Depreciation & Amortization reached $156.6 million in Q4 2025 per EW's latest filing, up from $155.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $156.6 million in Q4 2025 and bottomed at $139.6 million in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 4 years is $149.1 million, with a median of $150.0 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 7.11% in 2024, then rose 0.9% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $139.6 million in 2022, then rose by 3.8% to $144.9 million in 2023, then grew by 7.11% to $155.2 million in 2024, then grew by 0.9% to $156.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $156.6 million in Q4 2025, $155.2 million in Q4 2024, and $144.9 million in Q4 2023.